Core Viewpoint - The company held its 2024 annual performance briefing, addressing investor concerns about its core product, Panlong Qipian, and its strategies to mitigate price reduction risks from centralized procurement [1][2] Group 1: Company Performance and Product Positioning - Panlong Qipian is an exclusive patented traditional Chinese medicine and a Class A product under medical insurance, recognized in multiple national clinical guidelines and textbooks [1] - In the first half of 2024, Panlong Qipian ranked first in market share within the traditional Chinese medicine sector for musculoskeletal and rheumatic diseases, holding an 8.05% market share [1] - The company has developed a strong portfolio of products for rheumatic bone diseases, including Panlong Qipian, Panlong Jiu, and others, enhancing its market presence and competitiveness [1] Group 2: Strategic Initiatives and Future Development - The company plans to deepen evidence-based research on Panlong Qipian, enhance its competitive strategies, and actively develop untapped markets, particularly in county-level areas [2] - Future potential products, such as Xiaer Yanbian Granules and Bone Health Tablets, are expected to exceed one billion in market development, aiming for a dual sales drive in clinical and retail sectors [2] - The company will leverage its full industry chain advantages to strengthen its drug source base and accelerate innovation in traditional Chinese medicine [2]

Group 1 - The core activity involved a charity medical consultation and medicine donation event organized by the Shaanxi Securities Regulatory Bureau and the Shaanxi Listed Companies Association, featuring two pharmaceutical companies, Panlong Pharmaceutical and Kanghui Pharmaceutical [1][2] - Panlong Pharmaceutical emphasized its commitment to public welfare and health, aiming to integrate its corporate social responsibility into its operations by providing medical services and medicines directly to rural communities [1] - Kanghui Pharmaceutical expressed its dedication to improving life quality and human health, planning to continue various public welfare activities and deepen cooperation with local medical institutions [1] Group 2 - The event was a targeted initiative based on an assessment of villagers' health conditions, showcasing the social responsibility of the capital market and the service-oriented culture of the industry [2] - A total donation value of 149,800 yuan (approximately 14.98 million) was made, including 4,417 boxes of medicines and two medical devices, which were donated by the Shaanxi Listed Companies Association [2] - The medical consultation event served over 210 people, with more than 1,400 boxes of donated medicines distributed, including essential products for various health conditions such as gout, cardiovascular issues, and common colds [2]

经中国证券监督管理委员会证监许可[2023]1709号《关于同意陕西盘龙药业 集团股份有限公司向特定对象发行股票注册的批复》同意注册，陕西盘龙药业集 团股份有限公司（以下简称"盘龙药业"或"发行人"或"公司"）于2023年9 月21日向特定对象发行股票9,352,740股，发行价格为人民币32.29元/股，认购款 合计人民币30,200.00万元，扣除发行相关费用716.37万元（不含税），募集资金 净额为29,483.63万元。上述募集资金已于2023年9月27日到账，并经立信会计师 事务所（特殊普通合伙）审验，出具了《验资报告》（信会师报字[2023]第ZF11235 号）。中泰证券股份有限公司（以下简称"中泰证券"或"保荐机构"）作为盘 龙药业向特定对象发行股票项目的保荐机构，履行持续督导职责期限至2024年12 月31日。目前持续督导期已届满，中泰证券根据《证券发行上市保荐业务管理办 法》《深圳证券交易所上市公司自律监管指引第13号——保荐业务》等法规和规 范性文件相关规定，出具本保荐总结报告书。 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述 ...

中泰证券股份有限公司 关于陕西盘龙药业集团股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐人名称：中泰证券股份有限公司 被保荐公司简称：盘龙药业 | | --- | | 保荐代表人姓名：杨圣志 联系电话：010-59013887 | | 保荐代表人姓名：王彦忠 联系电话：010-59013948 | | 现场检查人员姓名：杨圣志 | | 现场检查对应期间：2024 年 1 月 1 日—2024 年 12 月 31 日 | | 现场检查时间：2025 年 4 月 14 日-4 月 16 日、2025 年 4 月 24 日-4 月 27 日 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段：查阅公司章程、三会规则及其他内部管理制度、三会运作资料；了解公司 | | 管理层的任职情况；查询公司股权结构及主要股东持股情况；与公司相关人员进行访谈 | | 等。 | | 1、公司章程和公司治理制度是否完备、合规 √ | | 2、公司章程和三会规则是否得到有效执行 √ | | 3、三会会议记录是否完整，时间、地点、出席人员 | | 及会议内容等要件是否齐备，会 ...

一、保荐工作概述 中泰证券股份有限公司 关于陕西盘龙药业集团股份有限公司 2024 年度持续督导保荐工作报告 | 保荐机构名称：中泰证券股份有限公司 | 被保荐公司简称：盘龙药业 | | --- | --- | | 保荐代表人姓名：杨圣志 | 联系电话：010-59013887 | | 保荐代表人姓名：王彦忠 | 联系电话：010-59013948 | | 公司及股东承诺事项 | 是否履行 | 未履行承诺的原因及解决措施 | | --- | --- | --- | | 1、公司关于向特定对象发行 A 股股票、公开发 | | | | 行可转换公司债券摊薄即期回报、采取填补措 | 是 | 不适用 | | 施及相关主体承诺 | | | | 2、公司控股股东、实际控制人关于减持意向的 | 是 | 不适用 | | 承诺 | | | | 3、公司控股股东、实际控制人限售安排和自愿 | 是 | 不适用 | | 锁定的承诺 | | | | 4、公司控股股东、实际控制人关于避免同业竞 | 是 | 不适用 | | 争、关联交易、资金占用方面的承诺 | | | | 5、公司分红承诺 | 是 | 不适用 | | 6、公司控股股东、实 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-022 陕西盘龙药业集团股份有限公司 关于举行 2024 年年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日在巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2024 年年度报告》。 为便于广大投资者深入了解公司情况，公司定于 2025 年 5 月 12 日（星期一） 15:00-17:00 在全景网举办 2024 年年度业绩说明会，本次年度业绩说明会将采用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 全 景 网 " 投 资 者 关 系 互 动 平 台 " （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：董事长谢晓林先生，副总裁张德柱先生， 董事会秘书吴杰先生，财务总监祝凤鸣先生，独立董事任海云女士，独立董事牛 晓峰先生，中泰证券股份有限公司保荐代表人杨圣志先生。 为充分尊重投资者、提升交流的针对 ...

Core Viewpoint - The company Panlong Pharmaceutical (002864.SZ) reported a slight decline in total revenue for 2024 but achieved a record high net profit, indicating strong financial performance and a solid dividend policy [1][2]. Financial Performance - In 2024, the company achieved total revenue of 974 million yuan, a year-on-year decrease of 0.71%, while net profit attributable to shareholders reached 120 million yuan, an increase of 8.91% [1]. - The net profit margin improved from 11.37% in 2023 to 12.31% in 2024 [1]. - For Q1 2025, the company reported a main revenue of 250 million yuan, a year-on-year increase of 19.08%, and a net profit of approximately 31.25 million yuan, up 0.33% [2]. Product Strength and Market Position - The key product, Panlong Seven Tablets, is a unique patented traditional Chinese medicine with strong market competitiveness, contributing significantly to the company's continuous profit growth over the past eight years [3][4]. - The market share of Panlong Seven Tablets in the traditional Chinese medicine market for musculoskeletal diseases was 7.72% in 2023 and increased to 8.05% in the first half of 2024, ranking first in the market [4]. Strategic Development - The company employs a "one body, two wings, three depths" strategy, focusing on industrial development in orthopedic chronic diseases, brand integration, and innovation in traditional Chinese medicine [6][10]. - The company has established a comprehensive marketing network across 30 provinces and has partnered with over 630 pharmaceutical companies, covering more than 4,800 hospitals and 7,000 pharmacies [7]. Research and Innovation - In 2024, the company significantly increased its R&D expenditure to approximately 37.54 million yuan, a year-on-year growth of 85.31%, achieving a record high since its listing [8]. - The company holds 65 valid patents, including 31 invention patents, and has developed a robust product pipeline with over 211 registered varieties of traditional Chinese medicine [8][9]. Future Outlook - The company is expected to expand its market presence further, with potential inclusion in new national clinical guidelines and essential drug lists, which could enhance its growth prospects [4][5].

Core Viewpoint - The financial report of Shanxi Panlong Pharmaceutical Group Co., Ltd. for 2024 shows a slight decline in revenue but a significant increase in net profit, indicating a stable growth trajectory since its listing in 2017 [1] Group 1: Financial Performance - The company's operating income for 2024 was 974 million yuan, a year-on-year decrease of 0.7% [1] - The net profit attributable to shareholders was 120 million yuan, reflecting an 8.9% year-on-year increase [1] - This marks the eighth consecutive year of net profit growth since the company went public [1] Group 2: Strategic Development - The company has implemented a strategic framework termed "One Body, Two Wings, Three Depths," focusing on orthopedic chronic diseases and leveraging national policies supporting traditional Chinese medicine [1][2] - The strategy includes enhancing governance and optimizing innovation across research, production, and sales [1][2] Group 3: Market Position and Growth Opportunities - Panlong Pharmaceutical has established a full industry chain encompassing medicinal herb planting, drug research, production, and sales [2] - The market share of its core product, Panlong Seven Tablets, continues to expand, and the traditional Chinese medicine segment is experiencing rapid growth [2] - The company has obtained research filing for 211 varieties of traditional Chinese medicine formula granules, laying the groundwork for new revenue streams [2] Group 4: Innovation and Collaboration - The company is responding to national policies by accelerating product innovation and has established a joint venture for new drug research with another pharmaceutical company [2][3] - The new research platform aims to enhance the company's capabilities in developing innovative drugs, particularly focusing on chronic disease treatments [3] Group 5: Future Growth Strategy - The company plans to leverage its established industry foundation for external growth through mergers and acquisitions, aiming to enhance its strategic positioning [3] - The dual strategy of "innovation development + merger expansion + integrated industry chain" is designed to adapt to market changes and drive new growth engines [3]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-017 陕西盘龙药业集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第四届董事会第二十四次会议、第四届监事会第二十次会议分别审议通过 了《关于公司 2024 年度利润分配预案的议案》，并将该议案提交公司 2024 年年 度股东会审议。现将该分配预案的基本情况公告如下： 一、利润分配预案的基本情况 1、经立信会计师事务所（特殊普通合伙）审计，并出具的标准无保留意见 审计报告（信会师报[2025]第 ZF10390 号）确认，截至 2024 年 12 月 31 日，公 司 2024 年度合并归属于上市公司股东的净利润为 120,271,592.81 元，截至期末 合 并 报 表 未 分 配 利 润 为 659,732,692.20 元 ； 其 中 母 公 司 实 现 净 利 润 118,531,359.46 元，提取法定盈余公积金 11,853,135.95 ...

净利润连续8年增长 4月24日晚间，盘龙药业（002864）发布2024年年报，2024年公司实现营业总收入9.74亿元，同比微降 0.71%；实现归母净利润1.2亿元，同比增长8.91%，净利润创历史新高，且连续8年呈现正增长。2024 年，公司经营活动现金流净额为1.57亿元，截至2024年末，公司货币资金余额为11.69亿元，均创历史新 高，充沛的现金流为公司未来发展奠定坚实基础。 证券时报·数据宝统计，从目前已经披露年报的数据来看，中药行业上市公司中，盘龙药业是仅有的过 去8年净利润连续增长的3家公司之一。 公司同一天发布2025年一季报，今年第一季度延续稳健增长趋势。报告期内，公司实现营业总收入2.5 亿元，同比增长19.08%；实现归母净利润0.31亿元，同比增长0.33%，环比增长1.79%。 2024年年报显示，盘龙药业拥有通过新版国家GMP认证的片剂、胶囊剂等25条生产线及配套的检验、 科研设备，现已形成以全国独家专利、医保甲类品种盘龙七片为主导，涵盖风湿骨伤类、心脑血管类、 消化类、补益类、清热解毒类、儿科类、妇科类、肝胆类等12大功能类别、100多个品规的强大产品阵 容。 公司核心品种盘 ...